Substance P

What it is

Pain signals travel through the body because of a small messenger molecule your nervous system produces called Substance P. It is released whenever tissue is injured or inflamed, amplifying pain, triggering swelling, and playing a documented role in nausea, gut motility, and mood regulation. Understanding it has led directly to approved medicines used by millions worldwide.

The scientific side

Substance P is described as an 11-amino-acid neuropeptide belonging to the tachykinin family, with the sequence RPKPQQFFGLM-NH2, that functions as both a neurotransmitter and neuromodulator across the central and peripheral nervous systems. Its primary receptor is the neurokinin-1 receptor (NK1R), a G-protein-coupled receptor whose crystal structure was solved and published in 2018 (PMID 30538204), revealing a deep orthosteric binding pocket that is targeted by clinically approved antagonists including aprepitant. Substance P is co-stored and co-released with classical neurotransmitters from primary afferent C-fibers and from neurons in the dorsal horn of the spinal cord, brainstem, and limbic system. In pain and nociception, SP is released from peripheral nerve terminals in response to tissue injury, binding NK1 receptors on dorsal horn neurons to amplify pain signals — a process referred to as central sensitization. It also triggers neurogenic inflammation by acting on blood vessels and immune cells to produce vasodilation, plasma extravasation, and mast cell degranulation. In corneal injury models, SP overexpression is directly associated with vasodilation, pain, and inflammation, while NK-1R antagonism reduces pain perception and supports nerve fiber recovery (PMID 39761841). At the spinal cord level, neurokinin receptor signaling (NK1 and NK2) controls whether spinal circuits support adaptive or maladaptive pain responses; agonism at these receptors can block protective motor learning in response to nociceptive stimuli (PMID 17907839). In the emetic reflex, SP plays a documented role in both acute and delayed phases of chemotherapy-induced nausea and vomiting: NK1 antagonists abolish both phases of cisplatin-induced emesis in rat models (PMID 24641692), and central NK1-expressing neurons are required for the full magnitude of tachykinin-mediated vomiting (PMID 19485577). In the gastrointestinal tract, SP modulates smooth muscle contractility through NK1 receptors; in IBS models, NK1-mediated colonic contractile responses are enhanced (PMID 15633223), and elevated plasma SP levels correlate with stress-induced colonic hypermotility (PMID 22363728). SP also activates intestinal mucosal eosinophils to increase CRF synthesis, linking stress, SP signaling, and gut dysfunction in IBS-D (PMID 33244004). In the CNS, the SP/NK1R axis regulates neuroinflammation in multiple neurological disorders, and NK1 receptor antagonists have been investigated for potential antidepressant effects, migraine prevention, and neuroprotective applications (PMID 30260793). Tachykinins including SP are evolutionarily conserved across vertebrates and invertebrates and function broadly as neuromodulators in circuits governing pain, inflammation, autonomic function, and immune responses (PMID 31824255). The NK1 receptor's crystal structure confirms a narrow hydrophobic binding pocket distinct from peptide hormone receptors, which enables selectivity in drug design for antagonists such as aprepitant (PMID 30538204). Substance P's role in cortical spreading depression — the electrophysiological event underlying migraine aura — has also been demonstrated directly in rodent in vivo models (PMID 30518958).

Class: Endogenous neuropeptide; tachykinin family; undecapeptide neurotransmitter/neuromodulator

What it's studied for

• Pain transmission and central sensitization (nociceptive signaling) Preclinical (Animal) + Human mechanistic
• Neurogenic inflammation and neuroimmune signaling Preclinical (Animal) + In vitro
• Chemotherapy-induced nausea and vomiting (CINV) — NK1 pathway target Animal model (translational) + Approved clinical pathway
• Irritable bowel syndrome (IBS) — gut motility and visceral hypersensitivity Animal model + Human observational
• Neuroinflammation in neurological disorders and potential mood/CNS applications Preclinical + Review

Safety signals

• Vasodilation and hypotension with exogenous administration
• Pain sensitization and hyperalgesia from excess SP signaling
• Neurogenic inflammation and edema
• Promotion of cortical spreading depression (migraine risk)
• Gastrointestinal hypermotility and visceral hypersensitivity
• Potential neuroinflammatory contribution to CNS disorders

Contraindications

Community-reported dosing

All studies (11)

• PMID 15633223
• PMID 17907839
• PMID 19485577
• PMID 22363728
• PMID 24641692
• PMID 30260793
• PMID 30518958
• PMID 30538204
• PMID 31824255
• PMID 33244004
• PMID 39761841